A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
Status:
Completed
Trial end date:
2019-07-25
Target enrollment:
Participant gender:
Summary
This is a randomized double-blind Placebo-controlled, Phase 2 study comparing bryostatin to
placebo for the treatment of moderately severe to severe Alzheimer's disease in subjects not
receiving memantine treatment. The study is 15 weeks in duration, including a safety and
efficacy evaluation 30 days after the last dose of study drug. Subjects will receive 7 doses
of study drug during the study. The primary efficacy endpoint is defined as the change from
baseline to Week 13 in the Severe Impairment Battery (SIB) total score.